MX2022011437A - Degradadores de transductores de se?al y activadores de la transcripcion (stat) y usos de los mismos. - Google Patents

Degradadores de transductores de se?al y activadores de la transcripcion (stat) y usos de los mismos.

Info

Publication number
MX2022011437A
MX2022011437A MX2022011437A MX2022011437A MX2022011437A MX 2022011437 A MX2022011437 A MX 2022011437A MX 2022011437 A MX2022011437 A MX 2022011437A MX 2022011437 A MX2022011437 A MX 2022011437A MX 2022011437 A MX2022011437 A MX 2022011437A
Authority
MX
Mexico
Prior art keywords
degraders
stat
compositions
methods
same
Prior art date
Application number
MX2022011437A
Other languages
English (en)
Spanish (es)
Inventor
Bin Yang
Nan Ji
Xiaozhang Zheng
Xiao Zhu
Original Assignee
Kymera Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kymera Therapeutics Inc filed Critical Kymera Therapeutics Inc
Publication of MX2022011437A publication Critical patent/MX2022011437A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545Heterocyclic compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Detergent Compositions (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MX2022011437A 2020-03-17 2021-03-17 Degradadores de transductores de se?al y activadores de la transcripcion (stat) y usos de los mismos. MX2022011437A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202062990555P 2020-03-17 2020-03-17
US202063088945P 2020-10-07 2020-10-07
US202063123335P 2020-12-09 2020-12-09
US202163159102P 2021-03-10 2021-03-10
PCT/US2021/022794 WO2021188696A1 (en) 2020-03-17 2021-03-17 Stat degraders and uses thereof

Publications (1)

Publication Number Publication Date
MX2022011437A true MX2022011437A (es) 2022-10-03

Family

ID=77771311

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022011437A MX2022011437A (es) 2020-03-17 2021-03-17 Degradadores de transductores de se?al y activadores de la transcripcion (stat) y usos de los mismos.

Country Status (9)

Country Link
US (1) US20240016942A1 (https=)
EP (1) EP4121055A4 (https=)
JP (1) JP2023518422A (https=)
CN (1) CN115776891A (https=)
AU (1) AU2021238333A1 (https=)
CA (1) CA3170503A1 (https=)
IL (1) IL296334A (https=)
MX (1) MX2022011437A (https=)
WO (1) WO2021188696A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12570679B2 (en) 2019-03-29 2026-03-10 Regents Of The University Of Michigan STAT3 protein degraders
CN120574283A (zh) 2019-04-05 2025-09-02 凯麦拉医疗公司 Stat降解剂和其用途
CN115677831B (zh) * 2021-07-22 2026-03-17 杭州和正医药有限公司 拟肽类stat降解药物、组合物及应用
CA3239730A1 (en) * 2021-12-11 2023-06-15 Christopher De Savi Stat3 degraders and uses thereof
CA3253876A1 (en) * 2022-03-31 2023-10-05 Recludix Pharma, Inc. STAT MODULATORS AND THEIR USES
WO2024030628A1 (en) * 2022-08-05 2024-02-08 Kymera Therapeutics, Inc. Deuterated stat3 degraders and uses thereof
WO2024173291A1 (en) * 2023-02-13 2024-08-22 Regents Of The University Of Michigan Compounds and compositions as stat3 degraders and uses thereof
WO2024173298A1 (en) * 2023-02-13 2024-08-22 Regents Of The University Of Michigan Compounds and compositions as stat3 degraders and uses thereof
EP4709370A2 (en) * 2023-05-09 2026-03-18 Recludix Pharma, Inc. Stat degraders and uses thereof
WO2024238603A2 (en) * 2023-05-15 2024-11-21 Recludix Pharma, Inc. Stat degraders and uses thereof
EP4731622A1 (en) * 2023-06-20 2026-04-29 Regents of the University of Michigan Compounds and compositions as vhl ligands and stat3 degraders uses thereof
CN117024254B (zh) * 2023-08-10 2025-09-09 浙江大学衢州研究院 一种多氟苯酚的合成方法
WO2026007994A1 (zh) * 2024-07-03 2026-01-08 正大天晴药业集团股份有限公司 膦酸化合物及其用途
WO2026020004A1 (en) * 2024-07-19 2026-01-22 Gilead Sciences, Inc. Stat6 compounds
WO2026027675A1 (en) 2024-07-31 2026-02-05 Guerra Gonzalez Carmen Triple combination for use in the treatmet of cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019060742A1 (en) * 2017-09-22 2019-03-28 Kymera Therapeutics, Inc AGENTS FOR DEGRADING PROTEINS AND USES THEREOF
WO2020198435A1 (en) * 2019-03-26 2020-10-01 The Regents Of The University Of Michigan Small molecule degraders of stat3
US12570679B2 (en) * 2019-03-29 2026-03-10 Regents Of The University Of Michigan STAT3 protein degraders
CN120574283A (zh) * 2019-04-05 2025-09-02 凯麦拉医疗公司 Stat降解剂和其用途

Also Published As

Publication number Publication date
WO2021188696A1 (en) 2021-09-23
AU2021238333A1 (en) 2022-09-29
EP4121055A4 (en) 2024-04-24
IL296334A (en) 2022-11-01
CA3170503A1 (en) 2021-09-23
EP4121055A1 (en) 2023-01-25
CN115776891A (zh) 2023-03-10
JP2023518422A (ja) 2023-05-01
US20240016942A1 (en) 2024-01-18

Similar Documents

Publication Publication Date Title
MX2021012216A (es) Degradadores de transductores de señal y activadores de transcripción (stat) y usos de los mismos.
MX2022011437A (es) Degradadores de transductores de se?al y activadores de la transcripcion (stat) y usos de los mismos.
PH12023500015A1 (en) Irak degraders and uses thereof
PH12022551524A1 (en) Irak degraders and uses thereof
WO2021127283A3 (en) Irak degraders and uses thereof
PH12022551522A1 (en) Smarca degraders and uses thereof
MX2023003973A (es) Degradadores de transductores de señales y activadores de la transcripción (stat) y usos de los mismos.
PH12021500026A1 (en) Irak degraders and uses thereof
PH12023500023A1 (en) Cdk2 degraders and uses thereof
MX2021014441A (es) Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos.
WO2020243415A3 (en) Tead inhibitors and uses thereof
WO2024039901A3 (en) Cdk2 degraders and uses thereof
MX2020006812A (es) Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos.
WO2023049790A3 (en) Mdm2 degraders and uses thereof
MX2023009527A (es) Degradadores de la cinasa 4 asociada al receptor de interleucina 1 (irak4) y usos de los mismos.
MX2024005138A (es) Degradadores de cinasa-4 asociada al receptor de la interleucina-1 (irak-4) y sintesis de los mismos.
PH12021553018A1 (en) New egfr inhibitors
ZA202309446B (en) Rapamycin analogs and uses thereof
MX2025006853A (es) Degradadores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos
EP4438117A3 (en) Tyk2 inhibitors and uses thereof
MX2021004245A (es) Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos.
JOP20210060A1 (ar) معدلات لمضاد تريبسين ألفا-1
WO2018195397A3 (en) Indole ahr inhibitors and uses thereof
MX2018016038A (es) Compuestos y metodos para modular la funcion del acido ribonucleico (arn).
MX2020001793A (es) Inhibidores del receptor de hidrocarburos de arilo (ahr) y usos de los mismos.